On June 18th, observe a syndicated, simulated P&T session focused on the approvals of spesolimab, deucravacitinib, and tapinarof, and how these agents will be managed for psoriasis.
MMIT’s syndicated P&T Perspectives session provides qualitative and tangible feedback through a simulated P&T session that informs your brand’s strategy and enables you to understand how your product and/or competitor’s product will fare in an actual P&T Committee review.
Use P&T Perspectives to:
View a clip from a recent P&T session.